Teva Pharma raises Q2 revs, EPS guidance ahead of next week's full release
The co announced that it will host a conference call and webcast for the investment community on Wednesday, July 13, 2016 at 8:00 a.m. ET to communicate its preliminary non-GAAP financial results for the quarter ended June 30, 2016. The Company will also provide its preliminary non-GAAP financial outlook for the years 2016 - 2019, which will include its pending acquisition of the Actavis Generics business that is awaiting FTC clearance. Ahead of the release, the company said it now sees better than expected Q2 results:
--> Sees Q2 EPS of $1.19-1.22 (Prior $1.16-1.20) vs $1.17 Capital IQ Consensus Estimate; revs $4.9-5.0 bln (Prior $4.8-4.9 bln) vs $4.82 bln Capital IQ Consensus Estimate; Sees cash flow from operating activities of $1.10-1.1 bln (Prior $1.2-1.3 bln)